All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests
This article was originally published in The Rose Sheet
Executive Summary
In an update on discussions with industry about potential user fees to support FDA's OTC monograph program, CDER officials say "industry and public would suffer" absent new fees.